论文部分内容阅读
抗3-羟基3-甲基戊二酰辅酶A还原酶(HMGCR)抗体介导的坏死性肌病是近年逐渐被认识的一类疾病,该病与他汀类药物的使用密切相关。患者具有坏死性肌病的一般特点,通过抗HMGCR抗体阳性与其他类型的坏死性肌病相鉴别。多数患者可通过激素联合其他免疫抑制剂治疗可控制病情。文中回顾了该病的发病机制、流行病学、临床特点、诊断及鉴别诊断、治疗等研究现状,以加强临床医生对该病的认识。
Anti-3-hydroxy 3-methylglutaryl coenzyme A reductase (HMGCR) antibody-mediated necrotizing myopathy is a gradually recognized type of disease in recent years, the disease is closely related with the use of statins. Patients with the general characteristics of necrotizing myopathy, anti-HMGCR antibodies by positive and other types of necrotizing myopathy phase identification. Most patients may be able to control the disease through the combination of hormones and other immunosuppressive agents. The paper reviewed the pathogenesis of the disease, epidemiology, clinical features, diagnosis and differential diagnosis, treatment and other research status, to enhance clinicians awareness of the disease.